Printer Friendly

Articles from M2 Pharma (November 10, 2016)

1-20 out of 20 article(s)
Title Author Type Words
Aradigm reports higher net loss of USD8.2m for Q3 2016. Financial report 162
Assembly Biosciences begins Phase 1 clinical trial of ABI-H0731 for treating chronic hepatitis B virus infection. 239
BenevolentAI signs exclusive license for series of novel clinical stage drug candidates with Janssen Pharmaceutica. 216
Bristol-Myers Squibb partners with Infinity Pharmaceuticals to evaluate Opdivo in combination with IPI-549 in advanced solid tumors. 252
Emmaus Life Sciences submits New Drug Application for review of grade L-glutamine. 218
Evoke Pharma incurs higher net loss of USD3.0m in Q3 2016. Financial report 141
FDA Clears Joimax's Vaporflex, Legato Electrosurgical Probes. 273
MannKind resolves agreement with Sanofi for AFREZZA (insulin). 187
McGillin Promoted to Chief Commercial Officer at NeuroMetrix. 282
Medicure reports financial results for quarter ended 30 September 2016. Financial report 138
MEI Pharma's net loss reduces to USD4.3m for Q1 fiscal 2017. Financial report 155
Mylan reports financial results for nine months ended 30 September 2016. Financial report 159
Pacific West Medical to Distribute Paragonix SherpaPak Cardiac, Kidney Transport Systems. 272
Perrigo Company appoints Morgan Stanley to lead review of strategic alternatives for Tysabri royalty stream. 132
Pfizer awarded approval for IBRANCE for treating women with HR+/HER2- metastatic breast cancer in the EU. 286
RegeneRx admits first patients in Phase 3 US dry eye clinical trial with RGN-259. 299
Researchers at University of Illinois discover monobody that can block oncogene's activity. 183
Thermo Fisher Scientific, Hamilton Form Sample Storage Collaboration. 212
TransEnterix installs Senhance Robotic System Programme at Imperial College London and Imperial College Healthcare NHS Trust. 176
TransEnterix Partners with Getz Healthcare to Lead Robotic Sales, Service and Support. 208

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters